Loading…

Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors

Gatekeeper mutations are identified in only 50% of the cases at resistance to Anaplastic Lymphoma Kinase ( ALK )-tyrosine kinase inhibitors (TKIs). Circulating tumor cells (CTCs) are relevant tools to identify additional resistance mechanisms and can be sequenced at the single-cell level. Here, we p...

Full description

Saved in:
Bibliographic Details
Published in:NPJ precision oncology 2021-07, Vol.5 (1), p.67-67, Article 67
Main Authors: Oulhen, Marianne, Pawlikowska, Patrycja, Tayoun, Tala, Garonzi, Marianna, Buson, Genny, Forcato, Claudio, Manaresi, Nicolò, Aberlenc, Agathe, Mezquita, Laura, Lecluse, Yann, Lavaud, Pernelle, Naltet, Charles, Planchard, David, Besse, Benjamin, Farace, Françoise
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Gatekeeper mutations are identified in only 50% of the cases at resistance to Anaplastic Lymphoma Kinase ( ALK )-tyrosine kinase inhibitors (TKIs). Circulating tumor cells (CTCs) are relevant tools to identify additional resistance mechanisms and can be sequenced at the single-cell level. Here, we provide in-depth investigation of copy number alteration (CNA) heterogeneity in phenotypically characterized CTCs at resistance to ALK-TKIs in ALK -positive non-small cell lung cancer. Single CTC isolation and phenotyping were performed by DEPArray or fluorescence-activated cell sorting following enrichment and immunofluorescence staining (ALK/cytokeratins/CD45/Hoechst). CNA heterogeneity was evaluated in six ALK -rearranged patients harboring ≥ 10 CTCs/20 mL blood at resistance to 1 st and 3 rd ALK-TKIs and one presented gatekeeper mutations. Out of 82 CTCs isolated by FACS, 30 (37%) were ALK + /cytokeratins - , 46 (56%) ALK - /cytokeratins + and 4 (5%) ALK + /cytokeratins + . Sequencing of 43 CTCs showed highly altered CNA profiles and high levels of chromosomal instability (CIN). Half of CTCs displayed a ploidy >2n and 32% experienced whole-genome doubling. Hierarchical clustering showed significant intra-patient and wide inter-patient CTC diversity. Classification of 121 oncogenic drivers revealed the predominant activation of cell cycle and DNA repair pathways and of RTK/RAS and PI3K to a lower frequency. CTCs showed wide CNA heterogeneity and elevated CIN at resistance to ALK-TKIs. The emergence of epithelial ALK -negative CTCs may drive resistance through activation of bypass signaling pathways, while ALK -rearranged CTCs showed epithelial-to-mesenchymal transition characteristics potentially contributing to ALK-TKI resistance. Comprehensive analysis of CTCs could be of great help to clinicians for precision medicine and resistance to ALK-targeted therapies.
ISSN:2397-768X
2397-768X
DOI:10.1038/s41698-021-00203-1